Verisk Analytics, Inc. (VRSK) Stock Analysis
Is VRSK a good investment?
Verisk Analytics, Inc. (VRSK) has a Plutrex AI rating of 72.0/100 as of August 23, 2026, indicating a Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Profitability moat is structurally durable and industry-leading: operating margin 45.1% (+46.4% vs. industry 30.82%) and net margin 28.2% (+91.8% vs. industry 14.72%) reflect near-monopolistic pricing power in insurance analytics — these margins are not easily replicated and have been sustained across multiple business cycles; FCF of $1.056B provides massive capital allocation flexibility. Main concern: Court-mandated AccuLynx acquisition ($2.35B) remains UNCHANGED as a governance and FCF overhang — the Delaware Chancery Court ruling forces management to proceed with a deal they may have preferred to exit, introducing forced integration complexity, near-term FCF pressure (the $2.35B acquisition represents ~2.2x annual FCF), and balance sheet deterioration on an already highly leveraged structure (negative book equity); Headline: 'Verisk Responds to Delaware Chancery Court Ruling Regarding AccuLynx' confirms investor concern is real and unresolved.
Investment Summary
Verisk Analytics (VRSK) at $187.50 is a high-quality data analytics franchise with exceptional profitability (operating margin 45.1%, net margin 28.2%, FCF ~$1.06B) but trades at a stretched valuation (P/E 28.81x, PEG 1.99) relative to its modest revenue growth of 4.4%. The stock has risen 3.2% from our prior $181.67 entry midpoint to $187.50, moving above our prior recommended entry range of $178-$186 and modestly worsening the PEG from 1.92 to 1.99. The analyst consensus target of $240.24 implies 28.1% upside, but the court-mandated AccuLynx acquisition ($2.35B) remains an unresolved integration and FCF headwind. XactAI product adoption is gaining traction (Headline: 'Verisk's AI Expansion Gains Traction as Insurance Adoption Scales'), which is a genuine positive catalyst, but the AccuLynx court ruling overhang (Headline: 'Verisk Responds to Delaware Chancery Court Ruling Regarding AccuLynx') and references to a 'tumultuous year with significant decline' temper enthusiasm. At current prices, VRSK is a Hold — the business is excellent but the entry point has deteriorated modestly since our prior report.
Key Strengths
- Profitability moat is structurally durable and industry-leading: operating margin 45.1% (+46.4% vs. industry 30.82%) and net margin 28.2% (+91.8% vs. industry 14.72%) reflect near-monopolistic pricing power in insurance analytics — these margins are not easily replicated and have been sustained across multiple business cycles; FCF of $1.056B provides massive capital allocation flexibility
- PEG of 1.99 is 29.2% below the industry average of 2.81, making VRSK the most attractively valued peer on a growth-adjusted basis despite a 17.8% P/E premium — forward EPS growth of 12.7% (next year) and 10.9% (5-year) leads the peer group vs. industry averages of -0.63% and 6.50%; analyst consensus target of $240.24 implies 28.1% upside with broad institutional support
- XactAI product adoption is accelerating among insurance customers (Headline: 'Verisk's AI Expansion Gains Traction as Insurance Adoption Scales'), providing a credible organic growth catalyst that could help bridge the gap between 4.4% historical revenue growth and the 12.7% forward EPS growth projection — AI-driven product expansion is the most important near-term positive development
Key Concerns
- Court-mandated AccuLynx acquisition ($2.35B) remains UNCHANGED as a governance and FCF overhang — the Delaware Chancery Court ruling forces management to proceed with a deal they may have preferred to exit, introducing forced integration complexity, near-term FCF pressure (the $2.35B acquisition represents ~2.2x annual FCF), and balance sheet deterioration on an already highly leveraged structure (negative book equity); Headline: 'Verisk Responds to Delaware Chancery Court Ruling Regarding AccuLynx' confirms investor concern is real and unresolved
- Revenue growth of 4.4% vs. industry 16.42% (-73.2% relative gap) means VRSK's forward EPS growth leadership (12.7% next year) is almost entirely dependent on buybacks and margin expansion rather than organic top-line acceleration — historical earnings growth of -3.4% YoY directly contradicts the forward 12.7% projection; at $187.50 (above our prior $178-$186 entry range), the PEG has worsened from 1.92 to 1.99 and the margin of safety has narrowed, making the current price a less attractive entry point than 7 days ago
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
VRSK's profitability metrics are elite-tier: gross margin 59.8%, operating margin 45.1% (vs. industry 30.82%, a 46.4% premium), net margin 28.2% (vs. industry 14.72%, a 91.8% premium), and ROE of 444.1% (structurally amplified by negative book equity from aggressive buybacks). FCF of $1.056B is the backbone of the investment thesis — it funds debt service, buybacks, and the forced $2.35B AccuLynx acquisition. However, revenue growth of 4.4% (vs. industry 16.42%, a 73.2% discount) is the critical weakness: forward EPS growth of 12.7% (next year) and 10.9% (5-year CAGR) are heavily dependent on buybacks and margin expansion rather than organic top-line acceleration. Historical earnings growth of -3.4% YoY directly contradicts the forward 12.7% projection. P/E of 28.81x on a business with 4.4% revenue growth and negative historical earnings growth is stretched; PEG of 1.99 means investors pay nearly 2x the projected growth rate. Intrinsic value on a 22-25x earnings basis yields $143-$163, suggesting 15-30% premium at current prices. The D/E ratio is N/A (negative book equity), confirming extreme leverage vs. near-zero-debt peers (industry D/E: 0.05). Cash of $552.2M is adequate but modest relative to implied debt load.
News Sentiment
Verisk Analytics is navigating a pivotal moment as its artificial intelligence ambitions collide with a court-ordered acquisition and lingering questions about its growth trajectory. The data analytics giant, which serves the insurance industry with critical risk assessment tools, is seeing real momentum in its AI push — its XactAI product is gaining significant traction among insurance customers, according to recent reports headlined 'Verisk's AI Expansion Gains Traction as Insurance Adoption Scales.' That's the good news. The complicated news? A Delaware court has ordered Verisk to proceed with its $2.35 billion acquisition of AccuLynx, a roofing software company, even though the company appeared to want an exit from the deal. Verisk's public response to the ruling — captured in the headline 'Verisk Responds to Delaware Chancery Court Ruling Regarding AccuLynx' — signals that investors are watching this forced deal closely. Meanwhile, analysts are debating whether the stock's premium price tag is justified, with headlines like 'Is VRSK Worth Buying as Recurring Revenue Battles a Premium Valuation?' capturing the central tension. On the positive side, multiple outlets have labeled VRSK a 'Top Growth Stock for the Long-Term' and advised investors to 'Retain VRSK Stock in Your Portfolio.' The company's insurance data franchise remains deeply entrenched, and rising theft of high-value metals and technology is actually driving demand for more sophisticated claims analytics — a tailwind for Verisk's core business. The bottom line: Verisk is a high-quality business at a premium price, with an AI growth story gaining credibility but a forced acquisition creating near-term uncertainty.
Risk Assessment
PRIMARY RISK: The court-mandated AccuLynx acquisition ($2.35B ≈ 2.2x annual FCF) is the most acute near-term risk — forced integration of a $2.35B asset without management's full conviction introduces execution risk, margin pressure, and balance sheet deterioration on an already leveraged structure (negative book equity). If integration stumbles, the 12.7% forward EPS growth projection becomes unreachable. SECONDARY RISK: Revenue growth of 4.4% vs. industry 16.42% means any multiple compression (P/E from 28.81x toward 22-25x fair value) would produce 15-30% downside to $143-$163 intrinsic value range. TERTIARY RISK: Rising interest rates disproportionately impact VRSK vs. near-zero-debt peers (industry D/E: 0.05), as VRSK's leveraged balance sheet (negative book equity) makes it more sensitive to rate increases. MITIGATION: Stop loss at $170 (9.4% below current $187.50, 6.1% below entry midpoint $181) limits downside to near the DCF intrinsic value floor of $150-$165. FCF of $1.056B provides strong debt service capacity. XactAI adoption provides a credible upside catalyst if AI-driven revenue acceleration materializes.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is VRSK a halal stock?
Yes, Verisk Analytics, Inc. (VRSK) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for VRSK?
Verisk Analytics, Inc. (VRSK) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is VRSK a good investment?
According to Plutrex AI, VRSK has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in VRSK?
US stocks like VRSK can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in VRSK?
Plutrex AI identifies the main risks for VRSK by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.